Program
N-Acetylcysteinamide
Also written as “NPI-001”, “N-Acetylcysteine Amide” and “NACA”.
Its studies are mostly in Usher Syndromes · Cystinosis · Cognitive Dysfunction · Cerebral Amyloid Angiopathy, Familial, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nacuity Pharmaceuticals | 42 open or running | phase 3since Dec 16, 2025 | Apr 17, 2020 | Apr 2029phase 3 · NCT07710196 |
| Arctic Therapeutics | 22 open or running | phase 2since Mar 18, 2026 | Mar 18, 2026 | Dec 29, 2026phase 2 · NCT07716865 |
Also a collaborator on its studies: blueskin-as.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 17, 2020First study: phase 2 study in Usher SyndromesNew to Nacuity PharmaceuticalsNacuity Pharmaceuticals · NCT04355689 · 49 enrolled · Australia
- Aug 8, 2023Phase 2 study in CystinosisNacuity Pharmaceuticals · NCT05994534 · 8 enrolled · Australia
- Dec 16, 2025Phase 3 study in Retinitis PigmentosaPhase 3 reachedNacuity Pharmaceuticals · NCT07290530 · 80 planned
- Mar 18, 2026Arctic Therapeutics's first studies: 2 phase 2 studiesNew to Arctic TherapeuticsArctic Therapeutics · NCT07741526, NCT07716865
- Jul 13, 2026Phase 3 study in Retinitis PigmentosaNacuity Pharmaceuticals · NCT07710196 · 80 planned · United States
Ahead
- Dec 29, 2026Primary completion: phase 2 study in Cerebral Amyloid Angiopathy, FamilialArctic Therapeutics · NCT07716865
- Apr 30, 2027Primary completion: phase 2 study in Cognitive DysfunctionArctic Therapeutics · NCT07741526
- Apr 2029Primary completion: phase 3 study in Retinitis PigmentosaNacuity Pharmaceuticals · NCT07710196
- Jul 2029Primary completion: phase 3 study in Retinitis PigmentosaNacuity Pharmaceuticals · NCT07290530
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07710196Retinitis Pigmentosa · United States | 3 | Recruiting | Nacuity Pharmaceuticals | Apr 2029 | 80 |
| NCT07741526Cognitive Dysfunction · Denmark, Iceland | 2 | Active, not recruiting | Arctic Therapeutics | Apr 30, 2027 | 33 |
| NCT07716865Cerebral Amyloid Angiopathy, Familial · Iceland | 2 | Active, not recruiting | Arctic Therapeutics | Dec 29, 2026 | 15 |
| NCT07290530Retinitis Pigmentosa | 3 | Not yet recruiting | Nacuity Pharmaceuticals | Jul 2029 | 80 |
| NCT05994534Cystinosis · Australia | 2 | Completed | Nacuity Pharmaceuticals | May 26, 2026 | 8 |
| NCT04355689Usher Syndromes · Australia | 2 | Completed | Nacuity Pharmaceuticals | Jun 20, 2025 | 49 |
How it is read
Names in the registry
- “NPI-001”, 3 entries
- “N-Acetylcysteine Amide”, 1 entry
- “NACA”, 1 entry
- “N-acetylcysteine amide”, 1 entry
Codes read as this program: NPI001.
Conditions, from the studies’ own filings
- Usher Syndromes, 3 studies
- Cystinosis, 1 study
- Cognitive Dysfunction, 1 study
- Cerebral Amyloid Angiopathy, Familial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.